HomeCompareEPZM vs MO

EPZM vs MO: Dividend Comparison 2026

EPZM yields 136.05% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPZM wins by $15.31M in total portfolio value
10 years
EPZM
EPZM
● Live price
136.05%
Share price
$1.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15.39M
Annual income
$6,293,323.05
Full EPZM calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — EPZM vs MO

📍 EPZM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPZMMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPZM + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPZM pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPZM
Annual income on $10K today (after 15% tax)
$11,564.63/yr
After 10yr DRIP, annual income (after tax)
$5,349,324.59/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, EPZM beats the other by $5,323,689.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPZM + MO for your $10,000?

EPZM: 50%MO: 50%
100% MO50/50100% EPZM
Portfolio after 10yr
$7.74M
Annual income
$3,161,741.11/yr
Blended yield
40.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

EPZM
Analyst Ratings
10
Buy
5
Hold
1
Sell
Consensus: Buy
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPZM buys
0
MO buys
0
No recent congressional trades found for EPZM or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPZMMO
Forward yield136.05%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$15.39M$80.1K
Annual income after 10y$6,293,323.05$30,159.17
Total dividends collected$14.14M$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: EPZM vs MO ($10,000, DRIP)

YearEPZM PortfolioEPZM Income/yrMO PortfolioMO Income/yrGap
1← crossover$24,305$13,605.44$10,570$780.30+$13.7KEPZM
2$56,912$30,905.26$11,381$1,032.90+$45.5KEPZM
3$128,528$67,631.59$12,535$1,392.73+$116.0KEPZM
4$280,268$142,743.86$14,193$1,920.91+$266.1KEPZM
5$590,792$290,905.24$16,618$2,723.68+$574.2KEPZM
6$1,205,245$573,097.64$20,263$3,993.80+$1.18MEPZM
7$2,382,274$1,092,661.12$25,936$6,098.36+$2.36MEPZM
8$4,567,482$2,018,449.47$35,166$9,775.01+$4.53MEPZM
9$8,503,963$3,616,756.90$51,026$16,597.78+$8.45MEPZM
10$15,392,564$6,293,323.05$80,113$30,159.17+$15.31MEPZM

EPZM vs MO: Complete Analysis 2026

EPZMStock

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

Full EPZM Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this EPZM vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPZM vs SCHDEPZM vs JEPIEPZM vs OEPZM vs KOEPZM vs MAINEPZM vs PMEPZM vs BTIEPZM vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.